Type | Public | |
Founded | 1987 | |
HQ | South San Francisco, CA, US | Map |
Website | sunesis.com | |
Employee Ratings | More |
USD | |
---|---|
Net income (Q2, 2020) | (6.4m) |
EBIT (Q2, 2020) | (6.3m) |
Market capitalization (15-Jan-2021) | 52.3m |
Closing stock price (15-Jan-2021) | 2.9 |
Cash (30-Jun-2020) | 17.7m |
EV | 41.2m |
USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|---|---|---|
Revenue | 5.0m | 3.8m | 8.0m | 5.7m | 3.1m | 2.5m | 669.0k | 237.0k | 2.1m |
General and administrative expense | 8.3m | 9.2m | 10.8m | 23.1m | 18.7m | 16.1m | 13.5m | 11.3m | 9.9m |
R&D expense | 22.6m | 29.2m | 28.9m | 27.7m | 23.7m | 22.9m | 21.5m | 14.6m | 15.4m |
Operating expense total | 30.9m | 38.4m | 39.7m | 50.8m | 42.4m | 39.0m | 35.1m | 25.9m | 25.4m |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 1.0m | 1.5m | 265.0k | 2.0m | 2.0m | 2.0m | 2.0m | 2.0m | 854.0k | 854.0k | 854.0k | 683.0k | 640.0k | 610.0k | 610.0k | 669.0k | 237.0k | 120.0k | ||||||||||
General and administrative expense | 2.0m | 2.2m | 2.2m | 2.2m | 2.3m | 2.4m | 2.9m | 2.8m | 3.4m | 6.4m | 7.2m | 5.1m | 5.2m | 4.0m | 4.3m | 4.0m | 3.9m | 3.9m | 3.7m | 3.2m | 3.4m | 2.8m | 2.7m | 2.4m | 2.5m | 2.5m | 2.2m | 2.1m |
R&D expense | 6.0m | 6.2m | 6.6m | 8.1m | 6.9m | 7.4m | 7.7m | 7.0m | 7.6m | 7.2m | 6.9m | 4.5m | 6.3m | 5.3m | 6.2m | 6.6m | 5.3m | 6.2m | 4.9m | 6.8m | 4.0m | 3.8m | 3.6m | 3.2m | 3.7m | 3.5m | 3.7m | 4.3m |
Operating expense total | 7.9m | 8.4m | 8.8m | 10.3m | 9.2m | 9.8m | 10.6m | 9.8m | 11.0m | 13.6m | 14.2m | 9.6m | 11.5m | 9.3m | 10.5m | 10.6m | 9.1m | 10.1m | 8.6m | 9.9m | 7.3m | 6.6m | 6.3m | 5.7m | 6.2m | 6.0m | 5.9m | 6.3m |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 7.6m | 11.9m | 5.3m | 11.7m | 41.6m | 12.6m | 6.6m | 21.7m | 50.4m | 26.8m | 20.8m | 18.8m | 20.3m | 16.8m | 23.9m | 9.4m | 5.8m | 11.5m | 11.7m | 7.9m | 21.4m | 17.0m | 20.2m | 24.8m | 9.8m | 19.7m | 20.0m | 17.7m |
Prepaid Expenses | 1.4m | 1.8m | 1.9m | 1.6m | 1.7m | 1.2m | 998.0k | 1.0m | 1.1m | 1.1m | 1.3m | 1.5m | 1.2m | 796.0k | 701.0k | 831.0k | 840.0k | 714.0k | 840.0k | 1.3m | 1.5m | 1.5m | 1.3m | 1.6m | 2.2m | 2.2m | 1.8m | 1.7m |
Current Assets | 50.3m | 43.5m | 36.7m | 30.9m | 78.2m | 62.2m | 50.6m | 46.5m | 71.8m | 59.7m | 46.0m | 41.3m | 40.7m | 31.3m | 40.7m | 34.0m | 25.1m | 35.9m | 23.5m | 13.7m | 26.9m | 21.9m | 21.5m | 26.4m | 19.8m | 40.5m | 30.7m | 24.9m |
PP&E | 94.0k | 82.0k | 66.0k | 58.0k | 50.0k | 36.0k | 31.0k | 27.0k | 41.0k | 35.0k | 53.0k | 31.0k | 19.0k | 17.0k | 11.0k | 8.0k | 6.0k | 1.0k | 25.0k | 22.0k | 18.0k | 16.0k | 14.0k | 9.0k | 7.0k | 5.0k | 1.0k |
USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|---|---|---|
Net Income | (20.1m) | (44.0m) | (34.6m) | (43.0m) | (36.7m) | (38.0m) | (35.5m) | (26.6m) | (23.3m) |
Depreciation and Amortization | 56.0k | 31.0k | 20.0k | 29.0k | 27.0k | 11.0k | 9.0k | 9.0k | (70.0k) |
Accounts Payable | 242.0k | (580.0k) | 875.0k | 2.2m | (724.0k) | (582.0k) | (174.0k) | (304.0k) | (602.0k) |
Cash From Operating Activities | (22.8m) | (10.6m) | (37.4m) | (43.2m) | (38.7m) | (37.0m) | (36.1m) | (24.4m) | (22.2m) |
USD | Q2, 2011 |
---|---|
Financial Leverage | 1.3 x |
When was Sunesis Pharmaceuticals founded?
Sunesis Pharmaceuticals was founded in 1987.
Who are Sunesis Pharmaceuticals key executives?
Sunesis Pharmaceuticals's key executives are Steve R. Carchedi, Dayton Misfeldt and Judith A. Fox.
How many employees does Sunesis Pharmaceuticals have?
Sunesis Pharmaceuticals has 29 employees.
What is Sunesis Pharmaceuticals revenue?
Latest Sunesis Pharmaceuticals annual revenue is $2.1 m.
What is Sunesis Pharmaceuticals revenue per employee?
Latest Sunesis Pharmaceuticals revenue per employee is $71.5 k.
Who are Sunesis Pharmaceuticals competitors?
Competitors of Sunesis Pharmaceuticals include Northwest Biotherapeutics, Merrimack Pharmaceuticals and Clovis Oncology.
Where is Sunesis Pharmaceuticals headquarters?
Sunesis Pharmaceuticals headquarters is located at 395 Oyster Point Blvd, South San Francisco.
Where are Sunesis Pharmaceuticals offices?
Sunesis Pharmaceuticals has an office in South San Francisco.
How many offices does Sunesis Pharmaceuticals have?
Sunesis Pharmaceuticals has 1 office.
Receive alerts for 300+ data fields across thousands of companies